Antiphospholipid Syndrome
Unique accuracy in Antiphospholipid Syndrome Diagnostics.
About Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a common autoimmune disease. Characteristic symptoms include recurrent thromboses and pregnancy morbidities.
In addition to clinical criteria, the ELISA-based detection of antibodies against cardiolipin and / or beta-2-glycoprotein I is part of the latest APS classification criteria 2023.
For a more comprehensive diagnostic investigation, the determination of antibodies against additional phospholipids and phospholipid-binding proteins can be of significant importance.
Sebia offers the largest portfolio of efficient and innovative ELISA-based random access test systems for APS diagnostics. The reliable Alegria Monotests present results of highest quality due to a unique coating procedure for phospholipids and additional use of human beta-2-glycoprotein I as a cofactor.
Furthermore, the Alegria 2 device brings new, convenient and cost-efficient opportunities for random access analyses in routine diagnostic services.
Key benefits
Largest Alegria Monotest portfolio
for random access determination of antibodies against phospholipids and phospholipid-binding proteins.
Superior proprietary antigen coating procedure
and use of human beta-2-glycoprotein I as a cofactor in Alegria aPL Monotests.
Excellent
diagnostic efficiency and accuracy.
High reproducibility
and lot-to-lot consistency for robust and reliable test results.
ELISA-based Alegria Monotests
in compliance with the latest ACR/EULAR APS classification criteria 2023.
Unique flexibility
with Alegria 2 for optimal workflow efficiency.
Sebia's offer
Anti-Annexin V immunoassays are used for the in vitro determination of autoantibodies against annexin V in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-Annexin V IgG
- Alegria – ORG 243G
Anti-Annexin V IgG/IgM
- ELISA – ORG 643
Anti-Annexin V IgM
- Alegria – ORG 243M
Anti-beta-2-Glycoprotein I immunoassays are used for the in vitro determination of autoantibodies against beta-2-glycoprotein I in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-beta-2-Glycoprotein I IgA
- Alegria – ORG 221A
Anti-beta-2-Glycoprotein I IgG
- Alegria – ORG 221G
Anti-beta-2-Glycoprotein I IgG/IgM
- ELISA – ORG 521
Anti-beta-2-Glycoprotein I IgM
- Alegria – ORG 221M
Anti-beta-2-Glycoprotein I Screen
- Alegria – ORG 221S
Anti-Cardiolipin immunoassays are used for the in vitro determination of autoantibodies against cardiolipin in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-Cardiolipin IgA
- Alegria – ORG 215A
Anti-Cardiolipin IgG
- Alegria – ORG 215G
Anti-Cardiolipin IgG/IgM
- ELISA – ORG 515
Anti-Cardiolipin IgM
- Alegria – ORG 215M
Anti-Cardiolipin Screen
- Alegria – ORG 215S
Anti-Phosphatidic Acid immunoassays are used for the in vitro determination of autoantibodies against phosphatidic acid in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-Phosphatidic Acid IgG
- Alegria – ORG 237G
Anti-Phosphatidic Acid IgM
- Alegria – ORG 237M
Anti-Phosphatidyl Inositol immunoassays are used for the in vitro determination of autoantibodies against phosphatidyl inositol in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-Phosphatidyl Inositol IgG
- Alegria – ORG 236G
Anti-Phosphatidyl Inositol IgM
- Alegria – ORG 236M
Anti-Phosphatidyl Serine immunoassays are used for the in vitro determination of autoantibodies against phosphatidyl serine in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-Phosphatidyl Serine IgG
- Alegria – ORG 235G
Anti-Phosphatidyl Serine IgG/IgM
- ELISA – ORG 535
Anti-Phosphatidyl Serine IgM
- Alegria – ORG 235M
Anti-Phospholipid Screen immunoassays are used for the in vitro determination of autoantibodies against cardiolipin, phosphatidyl serine, phosphatidyl inositol, phosphatidic acid and beta-2-glycoprotein I in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-Phospholipid Screen IgG
- Alegria – ORG 229G
Anti-Phospholipid Screen IgG/IgM
- ELISA – ORG 529
Anti-Phospholipid Screen IgM
- Alegria – ORG 229M
Anti-Prothrombin immunoassays are used for the in vitro determination of autoantibodies against prothrombin in human serum or plasma samples.
The tests are intended to aid in the diagnosis of antiphospholipid syndrome (APS) in conjunction with other laboratory and clinical findings.
Anti-Prothrombin IgG
- Alegria – ORG 241G
Anti-Prothrombin IgG/IgM
- ELISA – ORG 541
Anti-Prothrombin IgM
- Alegria – ORG 241M
Alegria-Check APS are multi-parameter-specific serum controls for daily internal quality control for the respective antibody isotype.
Alegria-Check APS IgG
- Alegria – ORG 162-2X05
Alegria-Check APS IgG is validated for the following assays:
- Anti-Cardiolipin IgG – ORG 215G
- Anti-beta-2-Gylcoprotein I IgG – ORG 221G
Alegria-Check APS IgM
- Alegria – ORG 163-2X05
Alegria-Check APS IgM is validated for the following assays:
- Anti-Cardiolipin IgM – ORG 215M
- Anti-beta-2-Gylcoprotein I IgM – ORG 221M
Featured instruments for Antiphospholipid Syndrome
See all instruments
Related resources
See all resourcesAlegria 2 properties and workflow
Obtain your patients results with high flexibility reliability and efficiency with Alegria 2.
Customer Testimonial about the Alegria 2
The Alegria 2 provides the possibility of giving results to clinicians within a timeframe fitting clinical needs and helps to optimize the patient’s care pathway.
Scientific publications
See all publications
Learn more about our unique technologies
Interested in Antiphospholipid Syndrome?
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.